Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NW-301VT in Advanced Solid Tumors
NCT07474168Phase 1Active, not recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NW-301VT in solid tumor, sponsored by Zhejiang University. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Dec 2025; status: active, not recruiting.
02
Drugs
NW-301VT
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07474168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474168.